Embryo Editing's Unpaid Debt

2026-10-15

Precision is not safety. Embryo gene editing promises to prevent some inherited diseases, yet the ability to target a DNA sequence does not guarantee that an embryo will develop without unintended changes. The distinction matters enormously. With CRISPR-Cas9, an attempted correction can introduce damage that laboratory checks may miss, leaving any resulting child to carry the uncertainty.

The danger exceeds mistargeting. Although off-target mutations attract attention, breaks at the intended site can also produce large deletions or chromosome abnormalities, rather than the correction researchers sought. Not every cell agrees. Mosaicism occurs when an embryo contains genetically different cells, so a small biopsy may fail to represent the embryo as a whole. Detection has its limits. Even apparently reassuring results cannot establish lifelong safety, and edits could pass to descendants if they enter the cells that produce eggs or sperm. Research is not reproduction. Studying embryos under oversight does not establish that using edited embryos to initiate pregnancies is acceptable.

Consent remains an inheritance. Parents routinely make medical decisions for children, but heritable editing could impose consequences on people beyond the immediate patient, without their agreement. Benefit also needs scrutiny. For many families facing single-gene disorders, embryo testing during fertility treatment can identify unaffected embryos without editing, although that option does not work in every case. Access complicates the promise. Expensive interventions could deepen inequality, while pressure to select preferred traits could narrow society's tolerance of disability and difference. The embryo cannot answer. Before medicine writes a correction into a family line, it must ask whose definition of an error deserves permanence.

Recommendations